Evidence does not support the use of mite-proof impermeable covers, air filtration systems, or delayed exposure to solid foods in infancy.Allergic rhinitis is an immunoglobulin E–mediated disease, thought to occur after exposure to indoor and outdoor allergens such as dust mites, insects, animal danders, molds, and pollens.The newer, second-generation (ie, nonsedating) antihistamines are usually preferable to avoid sedation and other adverse effects associated with the older, first-generation antihistamines.
Patients should be educated about their condition and advised to avoid known allergens.
Often referred to as the nonsedating antihistamines.
They compete with histamine for histamine receptor type 1 (H1) receptor sites in the blood vessels, GI tract, and respiratory tract, which, in turn, inhibits physiologic effects that histamine normally induces at the H1 receptor sites.
Intranasal corticosteroids are the most effective treatment and should be first-line therapy for persistent symptoms affecting quality of life.
More severe disease that does not respond to intranasal corticosteroids should be treated with second-line therapies, including antihistamines, decongestants, cromolyn, leukotriene receptor antagonists, and nonpharmacologic therapies such as nasal irrigation.
Most cases of allergic rhinitis respond to pharmacotherapy.
Patients with intermittent symptoms are often treated adequately with oral antihistamines, decongestants, or both as needed.
GBR 1342, a CD38x CD3 bispecific antibody based on Glenmark’s proprietary BEAT® platform.
It targets CD38, a proven target in multiple myeloma.
If confirmed in clinical trials, GBR 1302 will constitute an innovative treatment for HER2 positive cancers, and potentially prove superior to the currently available monoclonal antibody treatments.
Glenmark has initiated a Phase 1 trial for GBR 1302 in Germany and will soon expand recruitment to the USA.